Related references
Note: Only part of the references are listed.Quaity of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
G. Chen et al.
ANNALS OF ONCOLOGY (2013)
Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry
Bing-Yen Wang et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Determinants of quality of life in advanced cancer patients with bone metastases undergoing palliative radiation treatment
Kinsey Lam et al.
SUPPORTIVE CARE IN CANCER (2013)
Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line
N. B. Leighl
CURRENT ONCOLOGY (2012)
Effect of cigarette smoking on quality of life in small cell lung cancer patients
Jun Chen et al.
EUROPEAN JOURNAL OF CANCER (2012)
Relationship Between Deficits in Overall Quality of Life and Non-Small-Cell Lung Cancer Survival
Jeff A. Sloan et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
Ji-Youn Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Health-Related Quality of Life in Non-Small-Cell Lung Cancer: An Update of a Systematic Review on Methodologic Issues in Randomized Controlled Trials
Lily Claassens et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Comparison of the quality of life between patients with non-small-cell lung cancer and healthy controls
Lukas Jyuhn-Hsiarn Lee et al.
QUALITY OF LIFE RESEARCH (2011)
Determinants of quality of life in patients with advanced cancer
Camilla Zimmermann et al.
SUPPORTIVE CARE IN CANCER (2011)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study
Giorgio V. Scagliotti et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer
Bjorn H. Gronberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Impact of chronic obstructive pulmonary disease on respiratory status and quality of life in newly diagnosed patients with lung cancer
Anant Mohan et al.
RESPIROLOGY (2007)
Does marital status impact survival and quality of life in patients with non-small cell lung cancer? Observations from the Mayo Clinic Lung Cancer Cohort
Aminah Jatoi et al.
ONCOLOGIST (2007)
Integrating health profile with survival for quality of life assessment
JS Hwang et al.
QUALITY OF LIFE RESEARCH (2004)
Share Paper
